Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Videocon in voluntary liquidation: Lenders may have to take huge haircuts

7h freepressjournal.in
Mumbai: In what could severely dent the chances of lenders to recoup over 587 billion rupees from bankrupt Videocon Industries Ltd, the company has admitted that it can no longer continue as a ‘going concern’ and that it is ascertaining its valuation on a liquidation basis. A business is considered a ‘going concern’ if it is operational and has a potential to generate profits.
511389 VIDEOIND SBAZ

0
Wintrust Financial Corporation Reports Record Second Quarter 2018 Net Income, an Increase of 38% Over Prior Year, and Year-to-Date Net Income of $171.6 million, an Increase of 39% Over Prior Year

15h globenewswire
ROSEMONT, Ill., July 17, 2018 (GLOBE NEWSWIRE) -- Wintrust Financial Corporation (“Wintrust” or “the Company”) (Nasdaq:WTFC) announced net income of $89.6 million or $1.53 per diluted common share for the second quarter of 2018 compared to net income of $82.0 million or $1.40 per diluted common share for the first quarter of 2018 and $64.9 million or $1.11 per diluted common share for the second quarter of 2017.
WTFCM WTFCW WTFPP WTFC SBAZ

0
An evening walk down Dalal Street | Sensex up almost 200 pts, Nifty back at 11,000

2018-07-17 moneycontrol
After starting the week on a negative note, the market on Tuesday looked to reclaim its positive momentum from last week, backed by sharp gains in midcaps. The Sensex managed to end the day almost 200 points higher, while the Nifty managed to end above 11,000-mark.
IOC 500469 532617 TCHQY HINDUNILVR FEDA 532755 532187 532461 FEDS 500696 500477 FEDERALBNK ASHOKLEY SBAZ INDIGO INDUSINDBK JETAIRWAYS FDBAY 530965 AKLD TECHM 539448 PNJZY PNB AKLS

0
SBI wants 70,000 employees who worked overtime during demonetisation to return compensation

2018-07-16 freepressjournal.in
The leading bank of India SBI has issued an order to its zonal incharge, to recover the compensation granted to employees of its associate banks for working overtime during the demonetisation period, ie November 10, 2016 to December 30, 2016.
SBAZ

0
SBI to organise outreach programme for farmers on July 18

2018-07-16 moneycontrol
Country's largest lender State Bank of India (SBI) will organise a nation-wide Kisan Mela on Wednesday as an outreach programme for farmers and to impart financial literacy. SBI said it expects to cover 10 lakh farmers through nearly 14,000 rural and semi-urban branches across the country in this Kisan Mela, to be held on July 18.
SBAZ

1
Market capitalisation of nine of top 10 most valued cos zoom Rs 1.58 lakh cr

2018-07-15 moneycontrol
Combined market capitalisation of nine of the 10 most valued companies surged by a whopping Rs 1,58,882.34 crore last week, helped by an overall strong broader market and smart surge in the valuation of Reliance Industries Ltd (RIL).
500325 KMBKY RELIANCE HINDUNILVR TTNQY MRZUY 532500 532540 HDB MARUTI 500180 RIGD KOTAKBANK 500696 HDFCBANK TCS 500247 RLNIY SBAZ

1
M-cap of nine of top 10 most valued firms zoom Rs 1.58 lakh cr

2018-07-15 thehindubusinessline
Over the last week, the Sensex recorded a significant rise of 883.77 points. File Photo - BusinessLine
500325 KMBKY RELIANCE HINDUNILVR TTNQY MRZUY 532500 532540 HDB MARUTI 500180 RIGD KOTAKBANK 500696 HDFCBANK TCS 500247 RLNIY SBAZ

0
SBI PO Prelim result 2018 to be released on July 15, read how to check

2018-07-14 freepressjournal.in
New Delhi: The results of SBI Probationary Officers (PO) Preliminary examination 2018 (SBI PO Prelim exam 2018) is going to be released on Sunday i.e. July 15. The results will be released by the State Bank of India (SBI) on their official website sbi.co.in.
SBAZ

0
SBI Clerk Prelim results 2018: Results to be declared on July 18, read how to check

2018-07-14 freepressjournal.in
New Delhi: The results of SBI Junior Associate (JA) Clerk Preliminary examination 2018 (SBI Clerk Prelim exams 2018) are going to be released by State Bank of India (SBI) soon. The results will be announced during the third week of July 2018.
SBAZ

5
Sensex hits fresh record high on firm global cues

2018-07-13 freepressjournal.in
Mumbai: The BSE Sensex hit a fresh record high of 36,740.07 points in opening session today driven by smart gains in Infosys, Coal India and Wipro, despite weak macroeconomic data released yesterday.
500820 500469 FEDA ASIANPAINT 533278 500470 532187 532461 FEDS HDFCBANK 500570 FEDERALBNK TATAMOTORS CLNDY SBAZ INDUSINDBK FDBAY TTST PNJZY TATASTEEL TATLY HDB 500180 PNB COALINDIA TTM

0
State Bank of India - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SBAZ

0
Arun Jaitley calls for more Centre-state cooperation in farm sector

2018-07-12 freepressjournal.in
Mumbai: Union minister Arun Jaitley today suggested a uniform set of policies for the agriculture sector across the country so that farmers benefit the most and their income doubles.
SBAZ

0
State Bank of India - News Clarification

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SBAZ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 856121108